Skip to content
DE

DIM supplements

Clinical review pending

DIM changes estrogen metabolism, but a benefit for symptoms has not been shown. An overview of the studies, supplement forms and key interactions.

Editorial draft. The medical statements and source attributions of the original text have not yet been independently verified; the text has been read in full and copyedited. Clinical sign-off is still pending.

What DIM is

Diindolylmethane (DIM) is the dimeric condensation product of indole-3-carbinol (I3C, a plant compound from the indole family found in cruciferous vegetables). I3C itself forms when the compound glucobrassicin (present in broccoli, Brussels sprouts and cauliflower) is hydrolyzed by the enzyme myrosinase during chewing or food processing. Once I3C reaches the acidic environment of the stomach, condensation produces DIM as the main bioactive end product.

DIM is sold directly as a dietary supplement because the conversion of I3C from food into DIM cannot be predicted reliably. Research on the compound focuses mainly on its effect on estrogen metabolism, in particular its ability to induce the hepatic enzymes CYP1A1/CYP1A2 (the liver enzymes that route estrogen down particular metabolic pathways). It is not a general “hormone balancer.” “Estrogen dominance” is a popular marketing term, not a recognized clinical diagnosis. Source

Chemistry: from glucobrassicin to the indole dimer

DIM belongs to the indole family of plant compounds; its formal name is 3,3’-diindolylmethane. The biosynthetic sequence starts with glucobrassicin in the tissue of cruciferous plants. When plant cells are broken open by chewing, chopping or cooking, the enzyme myrosinase is released and hydrolyzes glucobrassicin to I3C. In the acidic stomach, I3C undergoes spontaneous acid-catalyzed condensation. DIM is the predominant product, alongside smaller oligomers such as LTr1 and indolo[3,2-b]carbazole (ICZ).

DIM is considered the main bioactive end product of dietary I3C in humans. Its indole-dimer structure allows it to bind the aryl hydrocarbon receptor (AhR), which is central to the proposed mechanism. Comprehensive reviews of I3C-derived indoles confirm that DIM is the dominant systemic species after oral I3C intake. Source 1 Source 2

From cabbage to capsule

The dietary sources of glucobrassicin (and therefore of I3C and DIM) are the brassicas: broccoli, Brussels sprouts, cauliflower, kale and cabbage. Glucosinolate content varies a great deal with plant variety, growing conditions and cooking method. Boiling, for example, leaches out glucosinolates and inactivates myrosinase, which lowers the yield of bioactive indoles from a given serving of the vegetable. Source

The modern market for DIM supplements grew directly out of cancer chemoprevention research in the 1990s and 2000s. Preclinical work in HPV mouse models and early pilot trials in breast cancer survivors laid the groundwork for the estrogen metabolite ratio hypothesis, which DIM marketing still relies on. From around 2015, DIM was repositioned for the women’s hormone wellness market (perimenopause, PMS and as an add-on in PCOS), in step with growing interest in cruciferous plant compounds as a way to manage hormones on one’s own. Source 1 Source 2 Source 3

How it changes estrogen metabolism

The main effect discussed for DIM is the induction of the liver enzymes CYP1A1 and CYP1A2. These enzymes preferentially steer estrogen metabolism down the 2-hydroxylation pathway rather than the 16-alpha-hydroxylation pathway. The downstream result that matters for marketing is a shift in the urinary ratio of 2-OHE to 16-alpha-OHE metabolites: a surrogate endpoint, not a clinical one. This ratio is what the science behind many product claims refers to.

CYP1A induction and the 2-OH pathway

DIM acts as a ligand for the aryl hydrocarbon receptor (AhR, a cytosolic transcription factor). Once activated, AhR moves into the cell nucleus and upregulates phase I metabolizing enzymes, mainly CYP1A1 and CYP1A2. These enzymes preferentially 2-hydroxylate estradiol and estrone, which raises the urinary ratio of 2-hydroxyestrone (2-OHE) to 16-alpha-hydroxyestrone (16-alpha-OHE). Cell-line and mechanistic models also point to modulation of the PI3K/Akt/mTOR signaling pathway, although this evidence comes from preclinical research. Source 1 Source 2

Studies of human urinary metabolites have shown that DIM supplementation measurably shifts the 2-OH:16-alpha-OH ratio. A retrospective cohort study in premenopausal women documented significant changes in the urinary estrogen profile after DIM supplementation. A follow-up study in postmenopausal women using transdermal estradiol confirmed measurable changes in estrogen metabolism. The key caveat: the clinical value of the 2-OH:16-OH ratio as a biomarker of breast cancer risk has been explicitly questioned in the scientific literature. Moving a surrogate marker is not the same as lowering the risk of disease. Source 1 Source 2 Source 3

Why many products are built for better absorption

Because it dissolves so poorly in water, crystalline DIM has very poor oral bioavailability. Single-dose pharmacokinetic studies in healthy volunteers identified this absorption limit early on and drove the development of formulations with improved absorption. These typically use DIM dispersed in phosphatidylcholine, TPGS (d-alpha-tocopheryl polyethylene glycol succinate) or microcrystalline cellulose carriers. At equivalent doses, these carrier systems produce plasma DIM exposure several times higher than plain crystalline powder. Source

After oral intake, DIM undergoes significant first-pass metabolism in the liver, which further limits the systemic exposure from plain powder without special carriers. With absorption-enhanced formulations, Tmax is about 2 to 4 hours, and the short half-life supports the twice-daily dosing schedule used in most published studies. Because DIM is lipophilic, clinical trials routinely give it with a fat-containing meal to maximize absorption. Timing therefore matters alongside formulation. Source

What human studies show

The quality of the evidence varies widely depending on which DIM effect is being claimed. The strongest human data sit at the level of surrogate endpoints (urinary estrogen metabolite ratios), not at the level of clinical endpoints such as symptom relief or cancer prevention. The biomarker rationale behind most DIM marketing is itself disputed.

Evidence grades: Strong means two or more well-designed human RCTs on a clinically meaningful endpoint (ideally a meta-analysis with a consistent direction of effect) or a single very large randomized controlled trial (N>1,000) with reproducible methods. Moderate means one such RCT, several smaller RCTs with mixed results, or a single high-quality RCT on a surrogate endpoint. Limited applies when there are only small (N<50), short (<8 weeks) or methodologically weak human studies, or only observational human data. Animal/preclinical only means there are no completed human trials, only in vitro, animal-model or phase 1 safety data. Anecdotal means there is no controlled evidence, only case reports, testimonials or mechanistic plausibility not backed by published data.

Urinary 2-OH/16-alpha-OH estrogen ratio: moderate evidence

A retrospective cohort study in premenopausal women measured changes in the urinary estrogen profile directly during DIM supplementation and found significant shifts in the metabolite ratio. A 2025 study in postmenopausal women using transdermal estradiol reproduced measurable changes in estrogen metabolism. An earlier pilot in postmenopausal breast cancer survivors showed favorable changes in the 2-OHE:16-OHE ratio. An RCT in breast cancer patients treated with tamoxifen documented shifts in the metabolite ratio alongside changes in tamoxifen metabolism. Small studies show consistent changes in this surrogate endpoint. Sample sizes remain modest, and the clinical meaning of the ratio itself is disputed. Source 1 Source 2 Source 3 Source 4

Risk or recurrence of breast, cervical and prostate cancer: limited evidence

In cervical dysplasia, a small pilot study looked promising, and a double-blind phase IIa RCT reported positive results on surrogate endpoints, but both studies were small. Importantly, a separate RCT in low-grade cervical cytological abnormalities found no significant effect. For breast cancer, data from HPV16 mouse models, preclinical breast cancer prevention findings and biomarker modulation in tamoxifen-treated patients amount only to evidence at the level of mechanism and surrogate markers. It has not been shown that DIM prevents or treats cancer in humans; human data on clinical endpoints are conflicting or missing. Source 1 Source 2 Source 3 Source 4 Source 5

PMS, PCOS and perimenopausal symptoms: anecdotal reports

No controlled human studies have tested DIM against symptom endpoints in PMS, PCOS or perimenopause as primary endpoints. The marketing infers symptom relief from changes in estrogen metabolites in premenopausal women. That link has not been established clinically. A change in the urinary metabolite ratio is not the same as relief from hot flashes, cycle irregularities or mood symptoms. The advertised effect is inferred from a mechanism; studies have not yet shown it. Source

Androgen-estrogen balance in men: animal evidence only

Preclinical findings, including cell-line and animal-model work in prostate cancer, show interaction with the AhR and estrogen metabolism pathways in male tissue. There are no controlled human studies testing DIM for testosterone modulation in men. Marketing claims such as “controls estrogen in men” or “supports male hormone balance” sit somewhere between animal-only and anecdotal claims and should not be treated as proven effects. Source

Effects that have not been shown so far: It has not been shown that DIM prevents or treats breast, cervical or prostate cancer in humans. It has not been shown to “balance hormones” or resolve “estrogen dominance” (a term that does not correspond to any recognized clinical diagnosis). Controlled studies have not shown that it produces clinically meaningful changes in PMS, PCOS or perimenopausal symptom scores. It is not a substitute for hormone replacement therapy or a prescribed endocrine therapy.

Supplement forms and bioavailability

Form matters more for DIM than for most supplements. Because of its lipophilic, water-insoluble structure, crystalline DIM has very poor oral bioavailability. The absorption-enhanced formulations used in most human studies produce plasma exposure several times higher at equivalent doses. Standard supplement doses range from 100 to 300 mg. The formulation on the label therefore matters just as much as the milligram figure. Source

  • Crystalline DIM. Plain DIM powder in capsules, typically 100 to 200 mg. Bioavailability is very low because of poor water solubility. Most published human studies do not use this form.

  • Absorption-enhanced DIM. DIM particles dispersed in phosphatidylcholine, TPGS or microcrystalline cellulose carriers; typical doses are 100 to 300 mg DIM equivalent. Pharmacokinetic studies show plasma DIM exposure several times higher than with crystalline DIM. Most modern human studies use this form, including the 12-month tamoxifen cohort RCT, the premenopausal urinary metabolite cohort and the postmenopausal transdermal estradiol study. Source 1 Source 2 Source 3

  • I3C (parent compound). Indole-3-carbinol; typical supplement doses are 200 to 400 mg. It converts unpredictably in the stomach into DIM and other condensation products. Some older cervical dysplasia studies used I3C, not DIM. It cannot be swapped for DIM milligram for milligram.

Independent testing matters for product quality. The source article names certification by USP, NSF International or ConsumerLab as a way to check label claims and possible contaminants. For absorption-enhanced DIM, documented pharmacokinetic data on the specific carrier system is the most important quality marker, more than a mere “enhanced bioavailability” claim on the label. Standardization should state the percentage of DIM per capsule.

Two quality red flags worth mentioning: crystalline DIM sold at high doses without PK data is unlikely to deliver the plasma exposures used in published studies. “Proprietary blends” that combine DIM with several unstudied co-ingredients make it impossible to attribute any observed effect specifically to DIM.

Regulatory status (as of October 2026)

According to the source article, as of October 2026 DIM is sold in the United States as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA). It is not FDA-approved for any indication. The FDA has not raised any NDI (New Dietary Ingredient) objections specific to DIM. It has issued at least one warning letter naming a DIM product: in May 2017 it told BioTE Medical that labeling claiming BioTE DIM could reduce the risk of arteriosclerosis and protect against prostate enlargement made the product an unapproved drug. That letter was about disease claims on the label, not about the DIM ingredient itself. Cervical dysplasia studies of DIM were conducted under Investigational New Drug (IND) applications, but no New Drug Application (NDA) for approval was filed. The World Anti-Doping Agency (WADA) does not list DIM as a prohibited substance. Regulatory status should be checked regularly, since the rules for dietary supplements can change. Source 1 Source 2 Source 3

Safety, side effects and drug interactions

In published studies, DIM has been tested at doses of up to 300 mg/day for up to 12 months and showed a generally favorable tolerability profile. Large, long-term safety data, however, are lacking. Possible drug interactions through the induction of CYP enzymes are especially relevant.

Side effects reported in DIM studies

The adverse events reported most often in RCTs and pilot studies are mild and transient. Dark urine (a harmless color change caused by DIM metabolites) was documented in single-dose pharmacokinetic studies and in the 12-month tamoxifen cohort RCT. The studies also reported mild gastrointestinal discomfort, headache and mild nausea. Skin rash was noted as a less common event in the 12-month RCT in the tamoxifen cohort. A single ascending-dose study in healthy volunteers established the tolerability of absorption-enhanced DIM up to about 200 mg. Studies and case reports have documented these effects; the available evidence does not support labeling DIM across the board as either “safe” or “dangerous.” Source 1 Source 2

Medications it interacts with

  • Tamoxifen: serious interaction. A 12-month RCT in tamoxifen-treated breast cancer patients documented that DIM modulates both the estrogen metabolite ratio and tamoxifen metabolism via CYP-mediated pathways. DIM should be combined with tamoxifen only after explicit consultation with the treating oncologist. Source

  • CYP3A4/CYP1A2 substrates: moderate interaction. DIM induces CYP1A1/CYP1A2, which can change the plasma levels of co-administered drugs metabolized by these enzymes. Anyone taking prescription medication regularly should discuss DIM with the prescriber beforehand. Source

  • Hormonal contraceptives / HRT: moderate interaction. DIM shifts estrogen metabolism through CYP1A induction, leading to a theoretical reduction in circulating estrogen levels that could affect the efficacy of contraceptives or HRT. Consultation with the prescriber is required before use. Source

Pregnancy, breastfeeding and special groups

Pregnancy and breastfeeding: DIM should be avoided. There are no controlled human safety data at supplemental doses, and given its effect on estrogen metabolism, theoretical concerns are warranted. Thyroid conditions: DIM has been studied in patients with thyroid proliferative disease and may influence estrogen-mediated thyroid effects; with autoimmune thyroid disease or thyroid nodules, endocrinology advice is required before use. Impaired liver function: after oral intake, DIM is extensively metabolized in the liver, so caution is advised at higher doses when liver disease is present. Impaired kidney function: no controlled data are available. The usual caution applies. Source 1 Source 2

Who should avoid DIM or get medical advice first?

Several groups face considerable risk from DIM supplementation without appropriate clinical supervision. The source article names the following situations in particular:

  • People who are pregnant or breastfeeding: no controlled human safety data at supplemental doses.

  • Anyone taking tamoxifen or another CYP-metabolized chemoprevention or endocrine therapy. An RCT documented a direct interaction with tamoxifen metabolism. Source

  • Anyone taking warfarin or another anticoagulant without the prescriber’s approval and INR monitoring.

  • Anyone using hormonal contraceptives or HRT for whom altered estrogen metabolism could have clinical consequences.

  • Anyone with autoimmune thyroid disease, thyroid nodules or other thyroid conditions without endocrinology support.

  • Anyone with documented liver disease, at supraphysiological doses.

  • Children: there are not enough data on supplement doses in children.

If any of these applies, intake should be discussed with a doctor beforehand. The complete medication list and current lab values are relevant to that conversation.

I3C vs. DIM: which has the stronger evidence?

I3C is the dietary precursor; DIM is its main condensation product in the stomach. Both are sold as supplements, but only DIM reaches the body in measurable, relatively predictable amounts. This makes the two compounds differ considerably in their pharmacokinetics.

  • Source / chemistry. I3C: a hydrolysis product of glucobrassicin from cruciferous vegetables; acid-labile and rapidly converted in the stomach. DIM: the main condensation product of I3C in the acidic stomach; chemically the indole dimer 3,3’-diindolylmethane.

  • Bioavailability. I3C: broken down in stomach acid into several products, including DIM, LTr1 and ICZ. The systemic DIM yield is unpredictable. Crystalline DIM is poorly absorbed systemically. Absorption-enhanced DIM delivers plasma DIM several times higher than crystalline DIM at equivalent doses. Source

  • Best-supported effects. I3C: older work on cervical dysplasia and breast cancer biomarkers from the early 2000s. DIM: modern studies of human estrogen metabolism showing changes in the premenopausal urinary estrogen profile, changes in postmenopausal transdermal estradiol metabolism and changes in the metabolite ratio in the tamoxifen cohort. Source 1 Source 2 Source 3

  • Dose range studied. I3C: 200 to 400 mg/day. DIM (absorption-enhanced): 100 to 300 mg/day.

  • Key safety differences. I3C yields DIM plus other condensation products whose biological effects are less well described. DIM offers a more direct dose-exposure relationship; the tamoxifen interaction signal is specifically a DIM finding from a controlled trial.

  • Cost (relative). I3C: $. DIM (crystalline): $. DIM (absorption-enhanced): $$.

  • Regulatory status. Both are US dietary supplements under DSHEA. As of October 2026, neither is FDA-approved for any indication. WADA lists neither as prohibited.

For a more predictable dose-exposure relationship and for studies of the metabolite ratio, recent human studies use DIM with improved absorption. People who want to get the compound from food receive a mix of I3C, DIM and other indoles from cruciferous vegetables, but at a much lower and less consistent systemic exposure than a formulated supplement provides. The conversion of I3C to DIM in the stomach is real but variable; it is not a reliable substitute for a characterized DIM formulation when the goal is a measurable change in the metabolite ratio. For assessment, the source article names the urinary ratio of 2-OH/16-OH estrogen metabolites plus serum estradiol and SHBG.

What to measure before and after 12 weeks?

The mechanism discussed for DIM runs through CYP1A-mediated estrogen metabolism, which means its effects, if any, should show up in specific hormone markers. Subjectively perceived changes alone are not reliable proof that it works. The source article recommends comparable lab tests on day 0 and after 8 to 12 weeks: at the same lab, under the same morning conditions and, for women who menstruate, in the same cycle phase. It describes this as a precondition for telling a real effect apart from natural biological fluctuation.

  • Estradiol (E2): the primary circulating estrogen and the substrate for the 2-OH/16-OH metabolic pathways; the baseline value reflects current estrogen exposure and is used in DIM studies as a contextual variable.

  • Estrone (E1): the second most important estrogen, especially relevant in postmenopausal women, in whom E1 predominates over E2; useful alongside E2 for the full context of the estrogen axis.

  • 2-OH/16-OH estrogen metabolite ratio: this surrogate endpoint is the one that actually changes in DIM studies. Not every lab offers the test; its availability should be checked before the baseline measurement. Source

  • SHBG: binds estradiol and testosterone; reflects hepatic estrogen exposure and is a complementary measure to E2.

  • Total and free testosterone: relevant for men using DIM for estrogen modulation, or for women with PCOS or concerns about androgen excess.

Baseline measurements before starting provide objective reference points for later changes. Without them, an observed response cannot be distinguished from fluctuation due to cycle phase or regression to the mean.

When should you see an endocrinologist instead?

If estrogen-related problems are suspected (severe PMS, perimenopausal symptoms that affect quality of life, suspected PCOS, abnormal cervical cytology, a history of breast cancer or a family history of hormone-sensitive cancer), the appropriate route is an endocrinology or gynecology assessment with a full hormone workup. “Estrogen dominance” is not a recognized clinical diagnosis; diagnosis belongs in a medical examination with the right tests.

Many DIM promises rest on a disputed hypothesis about the metabolite ratio. Baseline measurements help put things in context, whether or not taking DIM later becomes an option. Source

Frequently asked questions

What is a DIM supplement?

DIM (diindolylmethane) is a metabolite derived from indole-3-carbinol (I3C), a compound found in cruciferous vegetables such as broccoli and cabbage. Research suggests that DIM may influence estrogen metabolism by favoring the 2-hydroxylation pathway, which may raise the ratio of 2-hydroxyestrone to 16-hydroxyestrone metabolites. Note: the clinical significance of this shift in the metabolite ratio as a biomarker of breast cancer risk has been formally questioned in the peer-reviewed literature.

What are DIM supplements used for?

DIM is marketed for estrogen metabolism support, for PMS, perimenopause and PCOS, as an add-on in hormone-dependent cancers and for estrogen modulation in men. The strongest human data show shifts in urinary estrogen metabolite ratios rather than clinical endpoints, with favorable 2-OHE:16-OHE changes in breast cancer survivors. DIM can shift urinary estrogen metabolite ratios: a surrogate marker whose clinical significance has been formally questioned in the peer-reviewed literature. Source 1 Source 2

What DIM dose has been used in studies?

Studies have used 100 to 300 mg/day of absorption-enhanced DIM for 4 to 12 weeks in premenopausal and postmenopausal women. Crystalline DIM has poor bioavailability, which is why most studies use phosphatidylcholine or TPGS carrier systems. Source 1 Source 2 Source 3

What side effects do DIM supplements have?

The side effects reported most often with DIM supplements are dark urine (a harmless color change caused by metabolites), mild gastrointestinal discomfort and headache. Because no controlled data exist, DIM should be avoided during pregnancy and breastfeeding. Caution is needed with anticoagulants or prescription drugs metabolized through CYP, including tamoxifen, since a 12-month RCT documented a direct interaction with tamoxifen metabolism. Source 1 Source 2

Are DIM supplements FDA-approved?

In the US, DIM is sold as a dietary supplement under DSHEA. As of October 2026, it is not FDA-approved for any indication, and the FDA has not raised any NDI objections specific to DIM. A 2017 FDA warning letter classified a DIM product as an unapproved drug because of disease claims on the packaging. The 2-OH:16-OH metabolite ratio that underlies most DIM marketing has been formally challenged as a breast cancer biomarker. Source

What is the difference between DIM and I3C?

I3C is the parent indole found in raw cruciferous vegetables; in your acidic stomach it converts into DIM (and into other, less studied condensation products). DIM delivers a more predictable dose than I3C, which converts unpredictably. Some early cervical dysplasia studies used I3C, while most modern studies of human estrogen metabolism use DIM. The two cannot be swapped milligram for milligram. Source

Who should avoid DIM supplements?

DIM should be avoided during pregnancy and breastfeeding because there are no controlled human safety data. Without the prescriber’s approval, it should not be combined with tamoxifen, anticoagulants or prescription drugs that are CYP substrates. Medical advice should be sought before use, and the complete medication list is needed for that. Source

Which blood tests should I have before starting DIM?

As baseline measurements, the source article names estradiol (E2), estrone (E1), the 2-OH/16-OH estrogen metabolite ratio where available, and SHBG. For men using DIM for estrogen modulation, it also names total and free testosterone. A repeat test after 8 to 12 weeks is meant to show whether measurable changes have occurred.

Sources and literature of the original text

  • Williams DE (2021). Indoles Derived From Glucobrassicin: Cancer Chemoprevention by Indole-3-Carbinol and 3,3’-Diindolylmethane. Frontiers in nutrition, 8, 734334. https://doi.org/10.3389/fnut.2021.734334

  • Amarakoon D, Lee WJ, Tamia G, Lee SH (2023). Indole-3-Carbinol: Occurrence, Health-Beneficial Properties, and Cellular/Molecular Mechanisms. Annual review of food science and technology, 14, 347-366. https://doi.org/10.1146/annurev-food-060721-025531

  • Connolly EL, Sim M, Travica N, Marx W, Beasy G, Lynch GS, Bondonno CP, Lewis JR, Hodgson JM, Blekkenhorst LC (2021). Glucosinolates From Cruciferous Vegetables and Their Potential Role in Chronic Disease: Investigating the Preclinical and Clinical Evidence. Frontiers in pharmacology, 12, 767975. https://doi.org/10.3389/fphar.2021.767975

  • Sepkovic DW, Stein J, Carlisle AD, Ksieski HB, Auborn K, Bradlow HL (2009). Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model. Cancer epidemiology, biomarkers & prevention, 18(11), 2957-64. https://doi.org/10.1158/1055-9965.EPI-09-0698

  • Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF (2004). Pilot study: effect of 3,3’-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutrition and cancer, 50(2), 161-7. https://doi.org/10.1207/s15327914nc5002_5

  • Reyes-Hernández OD, Figueroa-González G, Quintas-Granados LI, Gutiérrez-Ruíz SC, Hernández-Parra H, Romero-Montero A, Del Prado-Audelo ML, Bernal-Chavez SA, Cortés H, Peña-Corona SI, Kiyekbayeva L, Ateşşahin DA, Goloshvili T, Leyva-Gómez G, Sharifi-Rad J (2023). 3,3’-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways. Cancer cell international, 23(1), 180. https://doi.org/10.1186/s12935-023-03031-4

  • Newman M, Smeaton J (2024). Exploring the impact of 3,3’-diindolylmethane on the urinary estrogen profile of premenopausal women. BMC complementary medicine and therapies, 24(1), 405. https://doi.org/10.1186/s12906-024-04708-7

  • Newman MS, Smeaton J (2025). The impact of 3,3’-diindolylmethane on estradiol and estrogen metabolism in postmenopausal women using a transdermal estradiol patch. Menopause (New York, N.Y.), 32(7), 630-639. https://doi.org/10.1097/GME.0000000000002542

  • Stanczyk FZ (2020). The 2-/16α-Hydroxylated Estrogen Ratio-Breast Cancer Risk Hypothesis: Insufficient Evidence for its Support. The Journal of steroid biochemistry and molecular biology, 201, 105685. https://doi.org/10.1016/j.jsbmb.2020.105685

  • Reed GA, Sunega JM, Sullivan DK, Gray JC, Mayo MS, Crowell JA, Hurwitz A (2008). Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3’-diindolylmethane in healthy subjects. Cancer epidemiology, biomarkers & prevention, 17(10), 2619-24. https://doi.org/10.1158/1055-9965.EPI-08-0520

  • Vermillion Maier ML, Siddens LK, Uesugi SL, Choi J, Leonard SW, Pennington JM, Tilton SC, Smith JN, Ho E, Chow HHS, Nguyen BD, Kolluri SK, Williams DE (2021). 3,3’-Diindolylmethane Exhibits Significant Metabolism after Oral Dosing in Humans. Drug metabolism and disposition, 49(8), 694-705. https://doi.org/10.1124/dmd.120.000346

  • Thomson CA, Chow HHS, Wertheim BC, Roe DJ, Stopeck A, Maskarinec G, Altbach M, Chalasani P, Huang C, Strom MB, Galons JP, Thompson PA (2017). A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast cancer research and treatment, 165(1), 97-107. https://doi.org/10.1007/s10549-017-4292-7

  • Del Priore G, Gudipudi DK, Montemarano N, Restivo AM, Malanowska-Stega J, Arslan AA (2010). Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecologic oncology, 116(3), 464-7. https://doi.org/10.1016/j.ygyno.2009.10.060

  • Ashrafian L, Sukhikh G, Kiselev V, Paltsev M, Drukh V, Kuznetsov I, Muyzhnek E, Apolikhina I, Andrianova E (2015). Double-blind randomized placebo-controlled multicenter clinical trial (phase IIa) on diindolylmethane’s efficacy and safety in the treatment of CIN: implications for cervical cancer prevention. The EPMA journal, 6, 25. https://doi.org/10.1186/s13167-015-0048-9

  • Castañon A, Tristram A, Mesher D, Powell N, Beer H, Ashman S, Rieck G, Fielder H, Fiander A, Sasieni P (2012). Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. British journal of cancer, 106(1), 45-52. https://doi.org/10.1038/bjc.2011.496

  • Sarkar FH, Li Y (2004). Indole-3-carbinol and prostate cancer. The Journal of nutrition, 134(12 Suppl), 3493S-3498S. https://doi.org/10.1093/jn/134.12.3493S

  • U.S. Food and Drug Administration. (n.d.). Dietary supplement products & ingredients. https://fda.gov/food/dietary-supplement-products-ingredients

  • U.S. Food and Drug Administration. (2017, May 22). Warning letter: BioTE Medical, LLC. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bio-te-medical-520217-05222017

  • World Anti-Doping Agency. (2025, September). The Prohibited List: 2026. https://wada-ama.org/en/prohibited-list

  • Rajoria S, Suriano R, Parmar PS, Wilson YL, Megwalu U, Moscatello A, Bradlow HL, Sepkovic DW, Geliebter J, Schantz SP, Tiwari RK (2011). 3,3’-diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: a pilot study. Thyroid, 21(3), 299-304. https://doi.org/10.1089/thy.2010.0245

Origin and editorial review status

Translated and prepared for Nutrient Desk from the original article. Promotional membership, newsletter and lab offers have been removed. The bibliography is kept in its original form for unambiguous identification. Figures and source references were carried over; the assignment of evidence to individual statements must be checked before publication. This draft is not cleared for indexing.